

**Unaudited Financial Statements and Dividend Announcement  
For the First Quarter and Three Months Ended 31 August 2018**

**PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3) AND FULL YEAR RESULTS**

1(a)(i) An income statement and statement of comprehensive income, or a statement of comprehensive income (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year

	<b>Group</b>		<b>Change %</b>
	<b>3 months Ended</b>		
	<b>31 Aug 2018 (Unaudited) S\$'000</b>	<b>31 Aug 2017 (Unaudited) S\$'000</b>	
Revenue	3,845	3,922	-2.0%
<b><i>Other items of income</i></b>			
Other income	59	26	126.9%
<b><i>Items of expense</i></b>			
Changes in inventories	115	24	379.2%
Inventories and consumables used	(518)	(363)	42.7%
Employee benefits expense	(1,433)	(1,290)	11.1%
Depreciation of plant and equipment	(98)	(87)	12.6%
Operating lease expenses	(256)	(255)	0.4%
Other expenses	(412)	(392)	5.1%
Finance costs	(18)	-	N.M.
Share of results of an associate, net of tax	46	114	-59.6%
Profit before income tax	1,330	1,699	-21.7%
Income tax expense	(215)	(241)	-10.8%
<b>Profit for the financial period, representing total comprehensive income for the financial period</b>	<b>1,115</b>	<b>1,458</b>	<b>-23.5%</b>
<b>Profit and total comprehensive income attributable to:</b>			
Owners of the parent	878	1,190	-26.2%
Non-controlling interests	237	268	-11.6%
	<b>1,115</b>	<b>1,458</b>	<b>-23.5%</b>

N.M. – Not meaningful

**1(a)(ii) Notes to Consolidated Statement of Comprehensive Income**

<b>Profit for the financial period is stated after charging the following:</b>	<b>3 months Ended</b>	
	<b>31 Aug 2018 (Unaudited) S\$'000</b>	<b>31 Aug 2017 (Unaudited) S\$'000</b>
Amortisation of intangible asset	3	3
Depreciation of plant and equipment	95	84

**1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year**

	Group		Company	
	31 Aug 2018 (Unaudited) S\$'000	31 May 2018 (Audited) S\$'000	31 Aug 2018 (Unaudited) S\$'000	31 May 2018 (Audited) S\$'000
<b>ASSETS</b>				
<b>Non-current assets</b>				
Plant and equipment	1,282	1,359	26	28
Intangible assets	5,943	5,115	1	1
Investments in subsidiaries	-	-	6,585	5,808
Investments in associates	5,754	5,708	5,381	5,381
Available-for-sale financial assets	1,028	1,028	1,028	1,028
Held-to-maturity financial assets	2,000	2,000	2,000	2,000
Deferred tax assets	2	2	-	-
Advance payments	150	300	150	300
	16,159	15,512	15,171	14,546
<b>Current assets</b>				
Inventories	335	220	-	-
Trade and other receivables	1,532	1,708	3,291	2,974
Prepayments	214	211	62	68
Cash and cash equivalents	4,802	4,988	1,968	2,366
	6,883	7,127	5,321	5,408
<b>Total assets</b>	<b>23,042</b>	<b>22,639</b>	<b>20,492</b>	<b>19,954</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
Share capital	14,433	14,433	14,433	14,433
Treasury shares	(316)	(321)	(316)	(321)
Merger reserve	(815)	(815)	-	-
Other reserve	(7)	-	(7)	-
Retained earnings	4,285	3,407	3,386	2,674
<b>Equity attributable to owners of the parent</b>	<b>17,580</b>	<b>16,704</b>	<b>17,496</b>	<b>16,786</b>
Non-controlling interests	445	404	-	-
<b>Total equity</b>	<b>18,025</b>	<b>17,108</b>	<b>17,496</b>	<b>16,786</b>
<b>Non-current liabilities</b>				
Deferred tax liabilities	96	96	-	-
Derivative financial instruments	69	69	69	69
Provisions	84	84	13	13
	249	249	82	82
<b>Current liabilities</b>				
Trade and other payables	1,962	2,503	727	746
Bank borrowings	2,063	2,250	2,063	2,250
Current income tax payable	743	529	124	90
	4,768	5,282	2,914	3,086
<b>Total liabilities</b>	<b>5,017</b>	<b>5,531</b>	<b>2,996</b>	<b>3,168</b>
<b>Total equity and liabilities</b>	<b>23,042</b>	<b>22,639</b>	<b>20,492</b>	<b>19,954</b>

**1(b)(ii) Aggregate amount of group's borrowings and debt securities**

**Amount repayable in one year or less, or on demand**

<b>As at 31 August 2018 (Unaudited)</b>		<b>As at 31 May 2018 (Audited)</b>	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
-	2,063	-	2,250

**Amount repayable after one year**

<b>As at 31 August 2018 (Unaudited)</b>		<b>As at 31 May 2018 (Audited)</b>	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
-	-	-	-

**Details of collaterals**

Not applicable.

**1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.**

**Consolidated Statement of Cash Flows**

	<b>3 months Ended</b>	
	<b>31 Aug 2018 (Unaudited) S\$'000</b>	<b>31 Aug 2017 (Unaudited) S\$'000</b>
<b>Operating activities</b>		
Profit before income tax	1,330	1,699
Adjustments for:		
Amortisation of intangible assets	3	3
Depreciation of plant and equipment	95	84
Interest income	(33)	(11)
Interest expense	18	-
Share of results of an associate, net of tax	(46)	(114)
Operating cash flows before working capital changes	1,367	1,661
Working capital changes:		
Inventories	(115)	(24)
Trade and other receivables	176	(642)
Prepayments	(3)	23
Trade and other payables	(541)	156
Cash generated from operations	884	1,174
Income tax paid	(1)	-
Net cash from operating activities	883	1,174
<b>Investing activities</b>		
Interest received	33	11
Acquisition of associate	-	(1,637)
Acquisition of subsidiaries, net of cash acquired	(478)	(662)
Purchase of intangible assets	(4)	(4)
Purchase of plant and equipment	(18)	(18)
Net cash used in investing activities	(467)	(2,310)
<b>Financing activities</b>		
Dividends paid to non-controlling interests	(196)	-
Interest paid	(18)	-
Purchase of treasury shares	(201)	-
Repayments of bank borrowings	(187)	-
Net cash used in financing activities	(602)	-
Net change in cash and cash equivalents	(186)	(1,136)
Cash and cash equivalents at beginning of financial period	4,988	8,757
Cash and cash equivalents at end of financial period	4,802	7,621

**1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year**

**Consolidated Statement of Changes in Equity  
Group**

(Unaudited)

	Share capital S\$'000	Treasury shares S\$'000	Merger reserve S\$'000	Other reserve S\$'000	Retained earnings S\$'000	Equity attributable to owners of the Company S\$'000	Non-controlling interests S\$'000	Total equity S\$'000
Balance at 1 June 2018	14,433	(321)	(815)	-	3,407	16,704	404	17,108
<b>Profit for the financial period</b>	-	-	-	-	878	878	237	1,115
<b>Total comprehensive income for the financial period</b>	-	-	-	-	878	878	237	1,115
<b>Contributions by and distributions to owners</b>								
Issue of shares	-	206	-	(7)	-	199	-	199
Purchase of treasury shares	-	(201)	-	-	-	(201)	-	(201)
<b>Total transactions with owners</b>	-	5	-	(7)	-	(2)	-	(2)
<b>Transactions with non-controlling interests</b>								
Dividends	-	-	-	-	-	-	(196)	(196)
<b>Total transactions with non-controlling interests</b>	-	-	-	-	-	-	(196)	(196)
Balance at 31 August 2018	14,433	(316)	(815)	(7)	4,285	17,580	445	18,025

(Unaudited)

Balance at 1 June 2017	13,014	-	(815)	-	1,631	13,830	95	13,925
<b>Profit for the financial period</b>	-	-	-	-	1,190	1,190	268	1,458
<b>Total comprehensive income for the financial period</b>	-	-	-	-	1,190	1,190	268	1,458
<b>Contributions by owners</b>								
Issue of shares	1,419	-	-	-	-	1,419	-	1,419
<b>Total transactions with owners</b>	1,419	-	-	-	-	1,419	-	1,419
Balance at 31 August 2017	14,433	-	(815)	-	2,821	16,439	363	16,802

**Statement of Changes in Equity  
Company**

<b>(Unaudited)</b>	<b>Share capital S\$'000</b>	<b>Treasury shares S\$'000</b>	<b>Other reserve S\$'000</b>	<b>Retained earnings S\$'000</b>	<b>Total equity S\$'000</b>
Balance at 1 June 2018	14,433	(321)	-	2,674	16,786
<b>Profit for the financial period</b>	-	-	-	712	712
<b>Total comprehensive income for the financial period</b>	-			712	712
<b>Contributions by and distributions to owners</b>					
Issue of shares	-	206	(7)	-	199
Purchase of treasury shares	-	(201)	-	-	(201)
<b>Total transactions with owners</b>	-	5	(7)	-	(2)
Balance at 31 August 2018	14,433	(316)	(7)	3,386	17,496
<b>(Unaudited)</b>					
Balance at 1 June 2017	13,014	-	-	1,489	14,503
<b>Profit for the financial period</b>	-	-	-	87	87
<b>Total comprehensive income for the financial period</b>	-	-	-	87	87
<b>Contributions by and distributions to owners</b>					
Issue of shares	1,419	-	-	-	1,419
<b>Total transactions with owners</b>	1,419	-	-	-	1,419
Balance at 31 August 2017	14,433	-	-	1,576	16,009

**1(d)(ii) Details of any changes in the company’s share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.**

**Shares Capital – Ordinary Shares**

The Company’s issued and fully paid-up capital (excluding treasury shares) as at 31 August 2018 comprised 149,175,730 (31 May 2018: 149,175,730) ordinary shares. On 23 July 2018, the Company performed a share buy-back of 300,000 ordinary shares which were kept as treasury shares. Subsequently on 17 August 2018, the Company transferred 300,000 treasury shares to Dr. Jason Lim as satisfaction of the consideration shares in connection to the acquisition of 51.0% of the entire issued share capital in Jason Lim Endoscopy and Surgery Pte. Ltd. (“JLES”).

**Outstanding Convertibles**

The Company did not have any convertible instruments as at 31 August 2018 and 31 August 2017.

**Treasury Shares**

There were 459,900 treasury shares (representing 0.31% of the Company’s 149,175,730 ordinary shares (excluding treasury shares)) as at 31 August 2018. The Company did not have any treasury shares as at 31 August 2017.

**Subsidiary Holdings**

There were no subsidiary holdings as at 31 August 2018 and 31 August 2017.

**1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year**

	As at 31 August 2018	As at 31 May 2018
Total number of issued shares excluding treasury shares	149,175,730	149,175,730

**1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.**

The Company had transferred 300,000 treasury shares during the first quarter ended 31 August 2018 (“1QFY2019”) to Dr. Jason Lim as satisfaction of the consideration shares in connection to the acquisition of 51.0% of the entire issued share capital in JLES. Save for the abovementioned, there were no other sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.



**1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.**

Not applicable. There were no subsidiary holdings during and as at the end of the current financial period reported on.

**2. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice**

The figures have not been audited or reviewed by the Company's auditors.

**3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter)**

Not applicable. The figures have not been audited or reviewed by the Company's auditors.

**4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied**

Except as disclosed in paragraph 5 below, the accounting policies and methods of computation adopted in the financial statements for the reporting period are consistent with those disclosed in the most recently audited consolidated financial statements for the financial year ended 31 May 2018.

**5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change**

The Group has adopted the Singapore Financial Reporting Standards (International) ("SFRS(I)s") that is identical to the International Financial Reporting Standards with effect from 1 June 2018. The adoption of SFRS(I)s for the first time for the financial year ending 31 May 2019 does not result in any material changes to the Group's and the Company's current accounting policies and no material adjustment are required on transition to this new framework.

The Group has adopted SFRS(I) 9 Financial Instruments and SFRS(I) 15 Revenue from Contracts with Customers that are relevant to the Group's operations. The adoption of the new SFRS(I)s does not result in any material changes to the Group's and the Company's accounting policies and has no material effect on the amounts reported for the current financial period or the previous financial years.

6. **Earnings per ordinary share of the group for the current period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends**

Earnings per share ("EPS")	Group	
	First Quarter	
	31-Aug-18 (Unaudited)	31-Aug-17 (Unaudited)
Profit attributable to owners of the parent (S\$)	878,000	1,190,000
Weighted average number of ordinary shares in issue	149,094,208 <sup>(1)</sup>	148,933,195 <sup>(2)</sup>
Basic EPS (cents per share)	0.59	0.80
Fully diluted EPS (cents per share)	0.59 <sup>(3)</sup>	0.80 <sup>(3)</sup>

Notes:-

- (1) The weighted average number of ordinary shares in issue for the first quarter ended 31 August 2018 was computed based on 149,094,208 ordinary shares, adjusted for (i) purchase of 300,000 treasury shares; and (ii) transfer of 300,000 treasury shares to Dr. Jason Lim as satisfaction of the consideration for the acquisition of 51% of the equity interest in JLES.  
Items (i) were purchased on 23 July 2018; and (ii) was transferred to Dr. Jason Lim on 17 August 2018.
- (2) The weighted average number of ordinary shares in issue for the first quarter ended 31 August 2017 was computed based on 148,933,195 ordinary shares, adjusted for issue of (i) 448,000 ordinary shares to Dr. Lai Junxu for the acquisition of 51% of the equity interest in Medical L & C Services Pte. Ltd. and (ii) 1,860,000 ordinary shares to Ms. Jessie Low for the acquisition of 49% of the equity interest in MediNex Pte Ltd..  
Items (i) and (ii) were issued on 29 June 2017.
- (3) EPS on a fully diluted basis for the first quarter ended 31 August 2018 and the first quarter ended 31 August 2017 is the same as the basic EPS because the Company did not have any potentially dilutive ordinary shares during and as at the end of the respective financial periods.

7. **Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the**  
**(a) Current period reported on; and**  
**(b) Immediately preceding financial year**

Net asset value ("NAV")	Group		Company	
	31-Aug-18 (Unaudited)	31-May-18 (Audited)	31-Aug-18 (Unaudited)	31-May-18 (Audited)
NAV (S\$)	17,580,000	16,704,000	17,496,000	16,786,000
Number of ordinary shares in issue	149,175,730	149,175,730	149,175,730	149,175,730
NAV per ordinary share (S\$ cents)	11.78	11.20	11.73	11.25

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss:-

(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and

(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on

*Review for the performance of the Group for the first quarter ended 31 August 2018 ("1QFY2019") as compared to the first quarter ended 31 August 2017 ("1QFY2018").*

#### **CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME**

##### Revenue

The Group recorded a decrease of \$77,000 or approximately 2.0% in revenue for 1QFY2019 as compared to 1QFY2018. The decrease was mainly due to some doctors going away for holidays and reservist, resulting in reduced patient consultations and procedures done.

##### Inventories and consumables used

Inventories and consumables used increased by \$155,000 or approximately 42.7% due to an increase in medication, and purchases of consumables which were usually expensed off, that arose from new subsidiaries acquired after the first quarter of the previous financial year and during the current financial year; and more radiology and investigations tests carried out.

##### Employee benefits expense

Employee benefits expense increased by \$143,000 or approximately 11.1%, of which \$120,000 was attributable to increased headcount from new subsidiaries acquired after the first quarter of the previous financial year and during the current financial year; and remaining \$23,000 increase was due to increased headcount and annual increment.

##### Depreciation of plant and equipment

Depreciation of plant and equipment increased by \$11,000 or approximately 12.6% for 1QFY2019 as compared to 1QFY2018 due to additions of plant and equipment for new subsidiaries acquired after the first quarter of the previous financial year and during the current financial year.

##### Share of results of an associate, net of tax

Share of profits of an associate, net of tax, decreased by \$68,000 or approximately 59.6% for 1QFY2019 as compared to 1QFY2018 due to MediNex Pte. Ltd. ("MediNex") incurring higher operating expenses and the Company's lowered equity interest in MediNex from 49.0% in 1QFY2018 to 35.8% in 1QFY2019.

#### Profit before income tax

As a result of the abovementioned, profit before income tax decreased by \$369,000 or approximately 21.7% from \$1,699,000 in 1QFY2018 to \$1,330,000 in 1QFY2019.

#### Income tax expense

Income tax expense decreased by \$26,000 in 1QFY2019 due to lower profit recorded in the current period compared to the corresponding period in the previous financial year.

#### Profit after income tax

As a result of the abovementioned, profit after income tax decreased by \$343,000 or approximately 23.5% from \$1,458,000 in 1QFY2018 to \$1,115,000 in 1QFY2019.

### **CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

*The comparative performance for both the assets and liabilities are based on the Group's financial statements as at 31 August 2018 and 31 May 2018.*

#### Non-current assets

Plant and equipment decreased by \$77,000 mainly due to depreciation of plant and equipment, partially offset by additions of plant and equipment.

Intangible assets comprise goodwill and computer software. The increase in intangible assets was primarily due to the increase in goodwill of \$827,000 due to the acquisition of JLES in June 2018.

#### Current assets

Trade and other receivables decreased by \$176,000 mainly due to decreased trade receivables outstanding from patients in line with decreased revenue.

#### Current liabilities

Trade and other payables decreased by \$541,000 mainly due to decrease in trade payables in line with decreased revenue; and lower accrual of expenses such as bonus and audit fee during the current financial year.

Bank borrowings decreased by \$187,000 due to repayments of short-term loans for working capital purpose, drawn down during the previous financial year.

Income tax payable increased by \$214,000 due to provision for tax expenses for current financial year.

### **CONSOLIDATED STATEMENT OF CASH FLOWS**

#### Net Cash from Operating Activities

For 1QFY2019, the Group recorded net cash from operating activities of \$883,000 compared to net cash from operating activities of \$1,174,000 in 1QFY2018, due to lower operating receipts.

Net Cash used in Investing Activities

For 1QFY2019, net cash used in investing activities amounted to \$467,000 related mainly to the balance consideration of \$478,000 paid for the acquisition of JLES.

Net Cash used in Financing Activities

For 1QFY2019, net cash used in financing activities amounted to \$602,000 related to the payment of dividends to non-controlling interests of \$196,000; repayments of bank borrowings of \$187,000; and share buy-backs of \$201,000.

As a result of the abovementioned, the Group recorded a net decrease in cash and cash equivalents of \$186,000 in 1QFY2019.

**9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results**

Not applicable as no specific forecast or a prospect statement has been issued previously.

**10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

In 1QFY2019, the Group welcomed a new specialist, Dr. Jason Lim in mid August 2018. Dr. Jason Lim operates in two clinics at Mount Elizabeth Novena Specialists Centre and our Ghim Moh clinic. The Group will continue to look for opportunities and suitable partners in our expansion plans.

The Group expects the medical industry to remain challenging due to economic instability and market competition in the region which may affect the Group in the next reporting period and next 12 months.

**11. Dividend**

If a decision regarding dividend has been made: -

(a) Whether an interim (final) dividend has been declared (recommended); and

No

(b) Previous corresponding period (cents)

No

(c) The date the dividend is payable.

Not applicable

- (d) The date on which Registrable Transfers receive by the Company (up to 5.00pm) will be registered before entitlements to the dividend are determined.

Not applicable

**12. If no dividend has been declared/recommended, a statement to that effect**

No dividend has been declared or recommended.

**13. If the group has obtained a general mandate from shareholders for interested person transactions ("IPT"), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.**

The Group does not have a general mandate from shareholders for interested person transactions.

There were no IPTS of \$100,000 and above entered into in 1QFY2019.

**14. Use of IPO Proceeds**

The Company refers to the net cash proceeds amounting to \$6.18 million (excluding listing expenses of approximately \$1.68 million) raised from the IPO on the Catalist Board of SGX-ST on 3 November 2016.

As at the date of this announcement, the status on the use of the IPO net proceeds is as follows:

<u>Use of IPO net proceeds</u>	<u>Amount allocated (\$'000)</u>	<u>Amount allocated after Reallocation (\$'000)</u>	<u>Amount utilised (\$'000)</u>	<u>Balance (\$'000)</u>
Expand business operations locally and regionally	2,800	4,800 <sup>(1)(2)</sup>	(4,595) <sup>(3)</sup>	205
Expand surgical facilities	1,200	400 <sup>(2)</sup>	(112) <sup>(4)</sup>	288
Working capital	2,180	980 <sup>(1)</sup>	(650) <sup>(5)</sup>	330
<b>Total</b>	<b>6,180</b>	<b>6,180</b>	<b>(5,357)</b>	<b>823</b>

**Notes:**

- (1) S\$1.2 million of the net IPO proceeds initially allocated for the Group's working capital had been reallocated to expand the Group's business operations locally and regionally. Please refer to the Company's announcement on 1 June 2017 for further details.
- (2) As the Company has no immediate and definite plans to use a significant portion of the IPO net proceeds to expand the Group's surgical facilities, \$0.8 million of the IPO net proceeds initially allocated

for the Group's expansion of surgical facilities had been reallocated to expand the Group's business operations locally and regionally, primarily for the proposed acquisition of 51% of the equity interest in JLES. Please refer to the Company's announcement on 7 May 2018 for further details.

- (3) Utilised for the following:-
  - (a) investment in joint venture, HSN Healthcare Pte. Ltd. – \$800,000;
  - (b) acquisition of Julian Ong Endoscopy & Surgery Pte. Ltd. – \$1,569,100;
  - (c) acquisition of Medical L & C Services Pte. Ltd. – \$790,160;
  - (d) acquisition of HMC Medical Pte. Ltd. – \$673,000;
  - (e) acquisition of JLES – \$628,000; and
  - (f) acquisition of additional 50% stake in Medical Services @ Tampines Pte. Ltd. – \$135,000.
- (4) Utilised for purchase of medical equipment and consumables for the Company and Island Family Pte. Ltd..
- (5) Utilised for payments related to consultancy fee, professional fee, insurance, advertising and promotion and rental expenses.

**15. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1)**

The Company confirms that it has procured undertakings from all of its directors and executive officers in the required format.

**16. Negative Confirmation by the Board Pursuant to Rule 705(5) of the Catalist Listing Manual**

The Board of Directors of the Company confirms, to the best of their knowledge, that nothing has come to their attention which may render the unaudited financial results for the three months ended 31 August 2018 to be false or misleading in any material aspect.

**BY ORDER OF THE BOARD**

Dr. Heah Sieu Min  
Executive Director and Chief Executive Officer  
9 October 2018

*HC Surgical Specialists Limited (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 3 November 2016. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").*

*This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

*This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Jennifer Tan, Senior Manager, Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and Email: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg)).*